enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 100 shares, a decline of 50.0% from the February 28th total of 200 shares. Based on an average daily volume of 9,700 shares, the days-to-cover ratio is currently 0.0 days.

enGene Stock Down 8.8 %

enGene stock opened at $0.62 on Friday. The firm’s fifty day moving average price is $0.82 and its two-hundred day moving average price is $1.23. enGene has a 1-year low of $0.42 and a 1-year high of $5.35.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.